Robust Viral Load Reduction Successfully Achieved In Phase II Clinical (Hep C Treatment)

Robust Viral Load Reduction Successfully Achieved In Phase II Clinical
Medical News Today - Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) and L.G. Life Sciences, Ltd. announced principal findings from an open label, multi-center, dose-escalation Phase II clinical trial, evaluating the safety and antiviral activity of ANA380 (LB80380) in

AVI BioPharma Announces Hepatitis C Virus License Agreement with
dBusinessNews.com - Offering comprehensive Web design services to new economy enterprises across a wide range of platforms and technologies, Web Design Studio takes pride in delivering big-business Internet solutions to small and medium-sized businesses. PORTLAND -- AVI

CROI: Liver fibrosis and noninvasive monitoring tools in HIV/HCV
Aidsmap - In a poster presentation, Pablo Barreiro and colleagues from Madrid offered evidence that successful hepatitis C treatment can slow down and even reverse liver damage in HIV/HCV coinfected individuals. Standard treatment for both coinfected and

Alnylam Pharmaceuticals Reports Fourth Quarter and Year End 2005
Genetic Engineering News - Through December 31, 2005, Alnylam had financed $8.2 million of its capital expenditures under its $10.0 million equipment line of credit with Lighthouse Capital Partners V, L.P. The company's ability to draw down on this line of credit ended on

CROI: Rapid response predicts success in HIV/HCV coinfected patients
Aidsmap - Virological response to hepatitis C therapy after four weeks appears to predict who will have a successful response to a full course of treatment in HIV-positive people coinfected with hepatitis C genotypes 1 or 3, according to findings from two